F
or too many patients with cancer, pain requires as much effort to effectively control as it takes to manage the disease. MacDonald (2003) defi ned a diffi cult patient as one who does not assume the role expected by the healthcare provider, differs from the caregiver in beliefs and values, and causes the caregiver to experience self-doubt. Patients labeled as having "diffi cult pain management syndromes," that is, the outcomes of management are not those expected by providers, have many of MacDonald's proposed characteristics. They represent a wide spectrum of pathologies and psychological issues. The complexity of their pain management requires ongoing expert assessments, participation by practitioners from multiple disciplines, and consistent use of nonpharmacologic interventions. Goal setting must be done in the context of understanding who a patient is and the meaning of pain in his or her personal experience. Diffi cult pain management cases require up-front multidisciplinary communication, consistent care providers, and a team committed to using all possible tools appropriate and available to patients. Key concepts of care, based on the authors' experience, are
Recognition that pain is a multifaceted experience involving not only a tissue damage response but also a suffering and existential component Ongoing assessment and reassessment of the different etiologies of a patient's pain and the effectiveness of interventions Consistent use of analgesic principles and nondrug approaches Emphasis on the patient's-not the healthcare team's-goals Skilled patient-healthcare provider communication.
Difficult cases may begin with seemingly uncomplicated pathologic conditions such as breast cancer with bone metastasis. Complex psychological issues may override the pathologic component of the diagnosis and hinder pain management. Assessing the meaning of the pain experience to a patient is one of the most critical parts of formulating a plan of care. The assessment requires the establishment of trust in care providers. This requires a commitment of time because trust must be earned.
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Clinical pain management begins with a clear understanding of the etiology and pathology of a patient's basis for pain. Assessment includes a physical examination, medication history, and critical descriptive aspects of the physical and psychosocial pain. An intensity scale appropriate to the age, cognitive ability, and cultural background of the patient is used to determine baseline intensity and monitor the effectiveness of interventions. As the assessment is completed, a team approach should be used to examine the information and assist with developing a plan of care that is acceptable to the patient. The team may be complex, involving many specialists and care providers, or more limited, involving minimal specialists and basic care providers. When pain management is complex, it requires an interdisciplinary team that consists of providers such as an advanced practice nurse, anesthesiologist, rehabilitation medicine physician, physical or occupational therapist, psychosocial support specialist, pharmacist, and others. Maximizing the resources available is critical. The patient remains the center of the team throughout the management process.
Three clinical cases are presented in this article to illustrate the complexity of assessment and management of pain that nurses frequently encounter in their day-to-day clinical practice and to explain why input from a multidisciplinary team is important. Two of the cases presented include the use of oral methadone, perhaps refl ecting the increasing use of methadone in many cancer centers, especially when neuropathic pain is a key component of diffi cult-to-control pain or if patients have had unmanageable adverse side effects while receiving other opioids.
Case One
Intractable Pain: Where Do We Start?
Patient history: Mrs. J is a 50-year-old patient with widely metastatic colon cancer involving the bones. Her physician recently stopped her chemotherapy regimen because it was causing more burden than benefi t to her quality of life. She has been experiencing increasing pain despite taking 300 mg of extended-released morphine every eight hours. Her breakthrough medication is 30-60 mg of immediate-release morphine every two to three hours as needed for pain. Presently, she requires seven breakthrough doses daily. Her pain is currently a 6 on a 0-10 scale at rest and an 8 on movement; the pain is located in her lower abdomen with occasional radiation to her coccyx region. Her baseline pain is constant and aching in nature.
Despite frequent opioid titration, Mrs. J reports ongoing problems with opioid-related side effects, including occasional nausea, fatigue, sedation, decreased activity, and constipation. She is on an aggressive bowel regimen. Presently, she is taking 10 mg of methylphenidate (Ritalin ® , Novartis Pharmaceuticals, East Hanover, NJ) twice a day to combat sedation and fatigue with minimal benefi ts. She is reluctant to increase her dose of Ritalin because she may feel "wired." Mrs. J reports that her quality of life has been affected signifi cantly in a very negative way by the pain and symptoms she experiences constantly. She says that she has undergone periods of severe depression. She describes tremors in her extremities that are myoclonic jerks probably related to accumulation of the morphine metabolite.
Interventions
Clearly, Mrs. J is experiencing poorly controlled pain and doselimiting side effects related to her analgesic regimen. However, her disease process cannot be ruled out as a contributing factor to the perceived dose-limiting issues that include nausea, vomiting, myoclonic activity, and sedation. Consider a family meeting to review the previous strategies.
Evaluation of disease progression always should be considered if opportunities for treatment exist. Mrs. J may benefi t from radiation therapy if appropriate to her pain locations and likely responsiveness to radiation therapy. If maximum radiation dosages to the areas have been reached, further radiation may not be possible. However, exceptions occasionally are made based on goals of care, closeness to death, and likelihood that radiation therapy will produce rapid pain relief. Although chemotherapy has been stopped, could palliative chemotherapy be used to help decrease pain? If a patient has days or weeks to live, benefi t versus burden of each approach always must be considered.
Opioid rotation should be considered when intractable pain exists despite aggressive titration and severe side effects, as well as if previous opioid rotation has not included methadone, longacting oxycodone, hydromorphone, or a fentanyl patch. With the exception of methadone, where an even lower starting dose of the drug may be used, opioid rotation usually is initiated with a starting dose of the new drug at 50% of the previous equianalgesic dose if a patient's pain is well controlled or he or she has doselimiting side effects. This allows for cross-tolerance and a greater sensitivity to the effects of the drug. However, Mrs. J's pain is not well controlled because she requires seven breakthrough doses daily. Opioid rotation with a conversion to an equianalgesic dose of the new opioid would be appropriate. Remember that the fi rst dose of the new drug is an estimated fi gure. The only way to know if the dose is correct for a patient is to reassess for adequacy of pain relief and reduction of opioid-related adverse side effects-the reason for the rotation. Methadone should be considered when swallowing pills is an issue, medication cost is a concern, or neuropathic pain is present (Gazelle & Fine, 2002) .
If methadone is used, it also could address the neuropathic component of Mrs. J's pain (Paice, 2004) . Methadone may be initiated fi rst rather than adding a coanalgesic to keep the analgesic regimen as simple as possible. A coanalgesic, such as a tricyclic antidepressant, can be added for the neuropathic component of the pain if methadone is ineffective. Methadone titration demands careful monitoring because of the long half-life of the drug and the likelihood of drug accumulation resulting in sedation.
Figure 1 provides guidelines for converting from oral morphine to oral methadone. Because the current dose of extended-release morphine is 300 mg every eight hours, a starting dose of 30 mg of methadone every eight hours would be fairly comparable (Manfredi & Houde, 2003) . Close monitoring, assessment, and reassessment of the amount of pain relief obtained and the presence of side effects are critical. Clinical experience suggests that during the titration period of methadone, cautious concern for dosing should refl ect the knowledge of the long half-life of the drug and concern for patient sedation. This is different for other opioids where short half-lives of the drugs lower the risk of drug accumulation. More detailed information on methadone dosing can be found in the resources listed in the bibliography.
Clearly, certain individuals tolerate certain opioids differently, and some develop side effects. Mrs. J appeared to have myoclonic jerks from the morphine; therefore, opioid rotation to relieve the side effect should be considered. Ritalin can offer excellent benefi ts for sedation, fatigue, and depression, and further titration may help improve Mrs. J's quality of life. The titration of Ritalin may be delayed pending the change of opioids and the outcomes they produce. If Ritalin is causing Mrs. J to feel "wired," modafonil may be a useful alternative. Although Mrs. J has been on an aggressive bowel regimen, the treatment should be reevaluated because it is failing.
Invasive therapies always should be considered when individuals are suffering from intractable pain or side effects from analgesic therapies (Coyne, 2003) . Such interventions often are forgotten, yet approximately 10% of patients with pain would benefi t from their use. Intraspinal administration delivers opioids or other drugs into the epidural or intrathecal space, placing the drug in close proximity to the receptors in the dorsal horn of the spinal cord. The delivery of drugs via the epidural route accounts for a 10-fold difference in drug requirements; therefore, a patient receiving 100 mg per day of IV morphine needs only 10 mg per day of epidural morphine or 1 mg per day via the intrathecal route to achieve the same analgesia. In addition, other drugs such as local anesthetics may be added to the patient's regimen via this route (Coyne, Smith, Laird, Hansen, & Drake, 2005) . The bibliography provides sources of additional information on invasive therapies.
Coanalgesics or adjunct agents are medications that possess independent analgesic activity or counteract the side effects of analgesic agents (Miaskowski et al., 2005) . Mrs. J was on no coanalgesics or adjunct agents. Her pain appeared mainly visceral in nature; however, it did occasionally radiate, suggesting an element of neuropathic pain. A trial of tricylic antidepressants or anticonvulsants may offer some benefi t. Because bony disease was noted, the role of nonsteroidal anti-infl ammatory drugs (NSAIDs) should be explored as well.
Mrs. J clearly is suffering from her disease progression and the treatment of her pain. Psychosocial evaluation and support should be available and used. Patients suffering from ongoing pain or symptoms commonly experience depression, and the condition often is missed in cancer treatment. As a patient experiences periods of depression, greater assessment is needed in addition to possible psychiatric intervention. The problem should be evaluated and treated.
Nonpharmacologic interventions are a mandatory component of pain management for each patient. Providers must know and understand the meaning of pain to a patient. All patients benefi t from the opportunity to explain the meaning or impact of the pain on their life situations. They also may benefi t from simple, nonpharmacologic measures such as deep breathing and refocusing as well as more complex adjunct interventions such as music, art, pet therapy, and massage. A practice standard should be developed indicating that no pharmacologic intervention should ever be offered without a nonpharmacologic intervention being taught, suggested, or demonstrated at the same time.
Case Two The Challenge of Complex Physiologic and Psychological Pain
Patient history: Mrs. F, a 45-year-old homemaker with three children aged 11-23, was diagnosed with a locally invasive and slow-growing thymoma 10 years ago. Recent tests revealed signifi cant disease involving the right lung extending through the right diaphragm and the right lobe of the liver. The tumor also involved the central diaphragmatic region and the mediastinal chest and extended from the T-6 vertebra to the L-1 without spinal cord involvement or impingement.
Since diagnosis, Mrs. F's tumor treatment included a right, upper-wedge resection, radiation therapy and implants, and intermittent chemotherapy. Her medical history included type 2 diabetes, asthma, and disease-related depression and anxiety.
Mrs. F's social history is signifi cant with a history of drug abuse and a son who is on a methadone maintenance program. She is divorced and lives with her 11-year-old son, who has been "acting out at school" and frequently complains of headaches. She has a supportive family and friend network, with two sisters who live nearby, one of whom is her healthcare proxy. Her ex-husband remains involved in his younger son's life. Religion is extremely important to her. In times of distress, she turns to her faith and church support group as well as her family.
Mrs. F's pain is located in the right chest wall region and the mid-and lower-right paravertebral regions; it is chronic, and she describes the quality as aching, burning, sharp, and nonradiating. Her average pain score is moderate (5-6 on a scale of 1-10) with occasional brief episodes of lancinating pain rating a 10. Her pain is partially relieved with opioid drugs, but dose escalation
• For patients on 30-90 mg of oral morphine in 24 hours, the ratio of morphine to methadone should be 4:1 (60 mg of morphine daily = 15 mg of methadone daily). • For patients on higher doses of morphine daily, the ratio should be 12:1 (400 mg of morphine daily = 35 mg methadone daily).
The ratios provide starting doses for clinicians. Titration up or down is guided by a patient's response. Very close monitoring is required during the fi rst 7-10 days of rotating a patient to methadone. Increasing methadone dosages typically should be done no more frequently than every 48-72 hours. Although methadone titration and equianalgesic theories vary, a 10% rule is usually safe (10 mg of oral morphine = 1 mg of oral methadone). Mrs. F's pain has somatic and neuropathic components and is disease and treatment related. The temporal pattern of her pain is continuous, with episodes of breakthrough pain. From self-report, the quality of her pain suggests that she would benefi t from combination pharmacotherapy that included opioids, NSAIDs, and coanalgesics such as an anticonvulsant for the sharp, shooting component of the pain. She also would benefi t from a tricyclic antidepressant at night for the burning component of her pain, to help her sleep, and to address her depression. Her physical examination reveals a distended liver. Liver capsules were identifi ed as one of the sources of her pain, and the use of steroids was considered. Because constipation exacerbates her pain and because she is on a variety of drugs that would increase her risk for the complication, a rigorous bowel regimen is critical.
Treatment Options
Several factors in Mrs. F's medical history guided the current pharmacotherapy recommendations. Despite opioid rotation, sedation and confusion are a consistent problem for Mrs. F when opioids are escalated in response to increased pain, regardless of the use of psychostimulants and small doses of neuroleptics. The balance between adequate pain relief and minimal adverse side effects is diffi cult to achieve. The one opioid Mrs. F has not been exposed to is methadone. Using methadone would require careful monitoring during the initial titration phase because of the drug's long half-life. Methadone also was thought to be a good drug for Mrs. F because of data suggesting its effect on the N-methyl-D-aspartate antagonist receptors, which are implicated in neuropathic pain (Gazelle & Fine, 2002) .
Referrals were made for evaluation by the anesthesia pain group to see whether a type of nerve block, epidural, or intra-spinal route of drug administration would better control pain, signifi cantly decrease opioid requirements, and therefore lessen Mrs. F's centeral nervous system and gastrointestinal side effects. The decision was made not to use steroids at the time because of her diabetes. She was started on gabapentin with doses escalated to a maximum of 3,600 mg every 24 hours for the neuropathic component of her chest wall pain, and NSAIDs were continued. Lidoderm ® (lidocaine 5%, Endo Pharmaceuticals, Chadds Ford, PA) patches, 12 hours on and 12 hours off, were applied to the area of her chest wall for "burning" pain and were found to be helpful. Because Mrs. F has a history of drug abuse and a son in a methadone maintenance program, she initially was very reluctant to even consider using methadone for her pain. Through ongoing education regarding the use of methadone for pain management versus its use in methadone maintenance programs, as well as the likelihood that her methadone dose would end up being about 10% of her current opioid dose with fewer side effects, she agreed to the methadone rotation. She was evaluated by the anesthesia pain group, which suggested a trial of epidural opioids. However, she refused the intervention because it was "too invasive."
Mrs. F had many factors that contributed to her overall pain and suffering-spiritual, psychosocial, and existential. All needed to be addressed if her pain was to be controlled. The social worker, school and family counselor, psychiatrist, chaplain, integrative medicine staff, family, homecare nurse, and aide all played vital roles in her pain management plan.
Case Three When Patients Refuse "Standard" Pain Management Approaches
Patient history: Mrs. S is a 72-year-old retired schoolteacher. She is not married. She lives alone, except for her dear companion, her dog, but she has two nieces who are available to assist her. She presents to her physician with complaints of severe low back pain, radiating down and around her thigh. A neurologic examination is done, analgesic script is provided, and a referral is made for physical therapy. Although she did not indicate it initially, Mrs. S notes at the end of the clinic visit that she has a mass in her right breast. This unexpected physical fi nding illustrates the importance of a full physical examination that includes undressing the patient in the setting of pain assessment.
Mrs. S is referred to the breast care clinic. Examination by the surgeon reveals a 4 cm breast mass. Two axillary lymph nodes are palpable. She refuses a mammogram and biopsy. She does consent to spine fi lms, which show vertebral compression. The surgeon suggests that a magnetic resonance imaging test be done, but Mrs. S refuses further workup. A midlevel analgesic is prescribed for pain management. An appointment is made for the following week to review the situation with the patient, family, and surgeon.
Team concerns included Assessing the need for biopsy Determining whether poor pain control infl uenced Mrs. S's ability to trust the team and move forward with the diagnosis and treatment of breast cancer Building a trusting relationship with Mrs. S. Mrs. S returned to the clinic three times. Biopsy was presented to her as a way to confi rm if, indeed, the mass was breast cancer. If so, surgery and/or noninvasive treatment such as possible hormonal manipulation of the tumor were options. She continued to refuse and decided to allow only pain management as an intervention. However, she would not return to the clinic.
Issues confronted included No goal for pain management was agreed on. Pain assessments were made over the phone only, eliminating a clinical examination component.
Mrs. S refused home nursing care, and during the next 18-month period, some providers were reluctant to prescribe medications for her because she was not being physically assessed regularly. The patient refused to allow the team to contact her nieces.
Team Approaches
The team agreed that Mrs. S's pain assessments could be done via telephone. A consistent care provider contacted her to complete the pain assessment no less than once a month. Mrs. S agreed to few dose escalations and used opioids inconsistently despite coaching to use around-the-clock dosing. Nonpharmacologic interventions were used on a scheduled basis and as needed. Mrs. S's functional status and her ability to care for her companion dog became the barometer of the status of her pain management goal.
When Mrs. S believed that she needed further intervention, she allowed the team to admit her to the hospital, where she continued to struggle with pain management. When she was transferred to an inpatient hospice setting, the same pattern of analgesic care continued, with Mrs. S dictating goals that were diffi cult for the staff to understand and accept. She was unconscious for the fi nal 72 hours of her life. The staff noted that nonpharmacologic interventions such as the quiet presence of volunteers and staff members, soft lights, and classical music provided the most effective pain relief during the last weeks of her life.
Summary
Diffi cult cases in pain management are complex. Goals for pain management must be agreed on by a patient and care provider. The patient clearly guides the process. Often the goals of the patient may be far different from those of the care provider and may not be in the realm of the usual acceptable standard. For example, clinicians may set a threshold that pain levels greater than 6 on a scale of 1-10 may require further consultation, review, and a change in the intervention. However, patients may decide that this is not appropriate; provided that they are aware of the impact of their decision, this must be accepted. Patients must be educated about the realm of interventions. Review of these cases with pain experts will ensure that all possible approaches have been exhausted as all care providers continue to support patients along the disease continuum.
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